title: More about surfactant, oxygen, caffeine and chronic lung disease.
authors.forename: Máximo
authors.initials: M
authors.lastname: Vento
authors.forename: Tore
authors.initials: T
authors.lastname: Curstedt
authors.forename: Henry L
authors.initials: HL
authors.lastname: Halliday
authors.forename: Mikko
authors.initials: M
authors.lastname: Hallman
authors.forename: Ola D
authors.initials: OD
authors.lastname: Saugstad
authors.forename: Christian P
authors.initials: CP
authors.lastname: Speer
mesh_terms: D000818:Animals; D002110:Caffeine / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D010102:Oxygen Inhalation Therapy / Q000009:adverse effects*; D037661:Pulmonary Surfactant-Associated Proteins / Q000378:metabolism; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012121:Respiration, Artificial / Q000009:adverse effects*; D012307:Risk Factors; D015398:Signal Transduction; D016896:Treatment Outcome; D055397:Ventilator-Induced Lung Injury / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*
chemical_list: D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; D002110:Caffeine